{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:49:32Z","timestamp":1790621372339,"version":"4.1.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, is highly effective for glycaemic control and weight reduction. However, its real-world cardiovascular adverse event reporting profile remains incompletely characterised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) from the second quarter of 2022 (FDA approval of tirzepatide) through the third quarter of 2025. Disproportionality analysis was performed using the Reporting Odds Ratio (ROR) with a concurrent full-database comparator (all other drugs reported in the same quarterly files). Because consumers submitted 92.3% of reports, primary inference was drawn from analyses restricted to healthcare professional (HCP) reports (physicians and pharmacists). Subgroup analyses stratified by age, sex, and body weight were conducted; weight-stratified analyses were confined to reports with documented body weight.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 103,693 unique tirzepatide reports were identified. Consumers accounted for 92.3% of submissions; body weight was documented in 5,881 reports (5.7%). In HCP-restricted analyses, tirzepatide was associated with persistently lower reporting odds for heart failure (ROR 0.18 [95% CI 0.07\u20130.43]). Similarly, no disproportionate reporting was detected for acute myocardial infarction (ROR 0.45 [0.19\u20131.08]), while remarkably, zero cases of angina or myocardial ischemia were reported in the HCP cohort. In contrast, no association was detected for atrial fibrillation (ROR 1.02 [0.58\u20131.80]) or tachycardia (ROR 1.01 [0.68\u20131.51]) in HCP reports. In weight-stratified analyses (full dataset, restricted to reports with documented weight), elevated RORs for tachycardia were observed in both weight groups (&amp;lt;95\u00a0kg: 1.91 [1.54\u20132.37]; \u226595\u00a0kg: 1.57 [1.20\u20132.05]); however, this finding was not replicated in the HCP-restricted analysis and should be interpreted with caution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world FAERS analysis using a concurrent full-database comparator and pre-specified stratification by reporter type, tirzepatide showed disproportionately low reporting of heart failure that was robust in HCP reports and across all subgroups. No reporting signal for atrial fibrillation, tachycardia, or ischemic events was detected after accounting for reporter bias. These findings provide pharmacovigilance evidence that complements the safety database of tirzepatide and generate hypotheses for ongoing cardiovascular outcome trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1785129","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T06:44:18Z","timestamp":1774248258000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Cardiovascular adverse event reporting profile of tirzepatide: a real-world pharmacovigilance analysis of heart failure, arrhythmias, and ischemic events"],"prefix":"10.3389","volume":"17","author":[{"given":"Daqiu","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Cardiology, Nanping First Hospital Affiliated to Fujian Medical University","place":["Nanping, Fujian Province, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixun","family":"Wang","sequence":"additional","affiliation":[{"name":"The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Health Science Center, Peking University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanxiong","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nanping First Hospital Affiliated to Fujian Medical University","place":["Nanping, Fujian Province, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nanping First Hospital Affiliated to Fujian Medical University","place":["Nanping, Fujian Province, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunxiang","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nanping First Hospital Affiliated to Fujian Medical University","place":["Nanping, Fujian Province, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanghua","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nanping First Hospital Affiliated to Fujian Medical University","place":["Nanping, Fujian Province, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1111\/dom.15725","article-title":"Comparative efficacy and safety of weekly tirzepatide versus weekly insulin in type 2 diabetes: a network meta-analysis of randomized clinical trials","volume":"26","author":"Ayesh","year":"2024","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"B2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet. Diabetes and Endocrinology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2337\/db21-1166","article-title":"GIPR is predominantly localized to nonadipocyte cell types within white adipose tissue","volume":"71","author":"Campbell","year":"2022","journal-title":"Diabetes"},{"key":"B4","doi-asserted-by":"publisher","first-page":"111983","DOI":"10.1016\/j.diabres.2024.111983","article-title":"Managing obesity in adults with type 1 diabetes","volume":"220","author":"Campos","year":"2025","journal-title":"Diabetes Research Clinical Practice"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e2025061118","DOI":"10.1073\/pnas.2025061118","article-title":"The neural basis for violations of Weber's law in self-motion perception","volume":"118","author":"Carriot","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-025-01699-6","article-title":"Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilance","volume":"17","author":"Donati","year":"2025","journal-title":"Alzheimer's Research and Therapy"},{"key":"B7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet London, Engl."},{"key":"B8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s10194-022-01424-w","article-title":"Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database","volume":"23","author":"G\u00e9rard","year":"2022","journal-title":"Journal Headache Pain"},{"key":"B9","doi-asserted-by":"publisher","first-page":"901","DOI":"10.4093\/dmj.2021.0314","article-title":"Effect of the glucagon-like Peptide-1 receptor agonists on autonomic function in subjects with diabetes: a systematic review and meta-analysis","volume":"46","author":"Greco","year":"2022","journal-title":"Diabetes and Metabolism Journal"},{"key":"B10","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cjca.2024.12.022","article-title":"Breaking Down bias: a methodological primer on identifying, evaluating, and mitigating bias in cardiovascular research","volume":"41","author":"Grubic","year":"2025","journal-title":"Can. Journal Cardiology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1111\/dom.16330","article-title":"Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: results from the Veradigm(R) database","volume":"27","author":"Hunter Gibble","year":"2025","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"B12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13195-025-01735-5","article-title":"Response to Xing et al.: post-marketing safety concerns with Lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database","volume":"17","author":"Irizarry","year":"2025","journal-title":"Alzheimer's Research and Therapy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N. Engl. Journal Medicine"},{"key":"B14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1161\/CIRCULATIONAHA.123.067505","article-title":"Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial","volume":"149","author":"Kosiborod","year":"2024","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"119057","DOI":"10.1016\/j.biopha.2026.119057","article-title":"Differential effects of the anti-obesity drug tirzepatide on adipose tissues: brown fat as a key target","volume":"195","author":"Mestres-Arenas","year":"2026","journal-title":"Biomed. and Pharmacotherapy = Biomedecine and Pharmacotherapie"},{"key":"B16","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.medj.2023.11.007","article-title":"SURMOUNTing body weight barriers in type 2 diabetes","volume":"4","author":"Novikoff","year":"2023","journal-title":"Med. (New York, N.Y.)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/cpt.3701","article-title":"FDA adverse event reporting system (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS","volume":"118","author":"Potter","year":"2025","journal-title":"Clin. Pharmacology Therapeutics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"101586","DOI":"10.1016\/j.molmet.2022.101586","article-title":"Genetic disruption of the gipr in Apoe(-\/-) mice promotes atherosclerosis","volume":"65","author":"Pujadas","year":"2022","journal-title":"Mol. Metabolism"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1111\/dom.16176","article-title":"Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials","volume":"27","author":"Rubino","year":"2025","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"B20","doi-asserted-by":"publisher","first-page":"101550","DOI":"10.1016\/j.molmet.2022.101550","article-title":"Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue","volume":"64","author":"Samms","year":"2022","journal-title":"Mol. Metabolism"},{"key":"B21","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat. Medicine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jacc.2024.04.038","article-title":"Semaglutide and NYHA functional class in obesity-related heart failure with preserved ejection fraction: the STEP-HFpEF program","volume":"84","author":"Schou","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e2446336","DOI":"10.1001\/jamanetworkopen.2024.46336","article-title":"Use of biologic or targeted synthetic disease-modifying antirheumatic drugs and cancer risk","volume":"7","author":"Sendaydiego","year":"2024","journal-title":"JAMA Network Open"},{"key":"B24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s11883-025-01319-6","article-title":"The expanding scope of GLP-1 receptor agonists: six uses beyond diabetes","volume":"27","author":"Sheth","year":"2025","journal-title":"Curr. Atherosclerosis Reports"},{"key":"B25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1042\/CS20242144","article-title":"Distinct effects of obesity and diabetes on the action potential waveform and inward currents in rat ventricular myocytes","volume":"139","author":"Shmygol","year":"2025","journal-title":"Clin. Science Lond. Engl. 1979"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1007\/s00125-023-05973-w","article-title":"Incretins and cardiovascular disease: to the heart of type 2 diabetes?","volume":"66","author":"Solini","year":"2023","journal-title":"Diabetologia"},{"key":"B27","doi-asserted-by":"publisher","first-page":"103385","DOI":"10.1016\/j.eclinm.2025.103385","article-title":"Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data","volume":"86","author":"Wang","year":"","journal-title":"EClinicalMedicine"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000004350","article-title":"Drug exposure before and during pregnancy and thromboembolic events: a disproportionality analysis from the FAERS database","author":"Wang","year":"","journal-title":"Int J Surg"},{"key":"B29","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/dom.15342","article-title":"Impact of a dual glucose-dependent insulinotropic peptide\/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: a systematic review and pairwise and network meta-analysis","volume":"26","author":"Yang","year":"2024","journal-title":"Diabetes, Obesity and Metabolism"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1785129\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T06:44:19Z","timestamp":1774248259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1785129\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":29,"alternative-id":["10.3389\/fphar.2026.1785129"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1785129","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"article-number":"1785129"}}